Entrar Registro gratuito

Last updated: 27 December 2019 at 7:10am EST

Arturo Araya Net Worth




The estimated Net Worth of Arturo Araya is at least $22.9 mil dollars as of 24 December 2019. Mr. Araya owns over 3,000 units of Brainstorm Cell Therapeutics stock worth over $2,410 and over the last 8 years he sold BCLI stock worth over $0. In addition, he makes $20,444 as Chief Commercial Officer at Brainstorm Cell Therapeutics.

Mr. Araya BCLI stock SEC Form 4 insiders trading

Arturo has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of BCLI stock worth $11,700 on 24 December 2019.

The largest trade he's ever made was buying 3,000 units of Brainstorm Cell Therapeutics stock on 24 December 2019 worth over $11,700. On average, Arturo trades about 600 units every 0 days since 2017. As of 24 December 2019 he still owns at least 8,608 units of Brainstorm Cell Therapeutics stock.

You can see the complete history of Mr. Araya stock trades at the bottom of the page.





Arturo Araya biography

Arturo O. Araya serves as Chief Commercial Officer of the Company. He also served as a director of the Company from February, 2017 to November, 2018. From 2002 to 2016, Mr. Araya worked for Novartis Pharmaceutical Corporation, where he served as the Vice President and Head of Global Commercial for Novartis’ Cell and Gene Therapies Unit (June 2014 to July 2016), where he led a cross-functional team to globally commercialize a portfolio of cell and gene therapies. In his prior role as Novartis’ Global Brand Leader for CTL019 (September 2012-May 2014), a CAR-T therapy, he was responsible for developing early launch plans, including worldwide and multiple indication forecasts and resource modeling. He has led the Oncology Unit for Novartis in seven countries (March 2002-August 2012). Prior to his tenure at Novartis, Mr. Araya was with Bristol-Myers Squibb Company (1999-2002), most recently as Associate Director of Marketing Intelligence, Business Development & Licensing. He earned an M.B.A. from the University of Michigan, and an M.A. and B.S. in Engineering from the University of Connecticut.

What is the salary of Arturo Araya?

As the Chief Commercial Officer of Brainstorm Cell Therapeutics, the total compensation of Arturo Araya at Brainstorm Cell Therapeutics is $20,444. There are 11 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of $1,639,680.



How old is Arturo Araya?

Arturo Araya is 49, he's been the Chief Commercial Officer of Brainstorm Cell Therapeutics since 2018. There are 10 older and 7 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.

What's Arturo Araya's mailing address?

Arturo's mailing address filed with the SEC is 3 University Plaza Dr #320, Hackensack, NJ 07601, USA.

Insiders trading at Brainstorm Cell Therapeutics

Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, eInternational Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.



What does Brainstorm Cell Therapeutics do?

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr



What does Brainstorm Cell Therapeutics's logo look like?

Brainstorm Cell Therapeutics, Inc. logo

Complete history of Mr. Araya stock trades at Brainstorm Cell Therapeutics

Data
#
Companhia
 Acionista maioritário
Trans.
Transação
 Ações Preço por ação Preço total Ações após Fonte
24 Dec 2019 BCLI Brainstorm Cell Therapeutics, Inc. Arturo Araya
Chief Commercial Officer
 Comprar 3,000 $3.90 $11,700
24 Dec 2019
8,608 ↗


Brainstorm Cell Therapeutics executives and stock owners

Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: